News Opexa Joins National Multiple Sclerosis Society to Sponsor Walk MS Opexa Joins National Multiple Sclerosis Society to Sponsor Walk MS by Patricia Silva, PhD | October 24, 2014 Share this article: Share article via email Copy article link The National Multiple Sclerosis Society‘sĀ Lone Star Chapter, which is sponsoring theĀ nonprofit organizationās annualĀ Houston-area Walk MSĀ fundraisers, has announced that Woodlands-based biopharmaceutical companyĀ Opexa Therapeutics, a company currently developing personalized immunotherapies for multiple sclerosis (MS), will also support the fundraising effort. This is the fourth consecutive year that the Lone Star Chapter of theĀ National Multiple Sclerosis Society has served as a sponsor of the event in Houston, but this year, Opexa alsoĀ decided to join the event which helps aboutĀ 68,000 patients suffering from the disease.Ā The Houston-area fundraisers take place between October and November at fourĀ locations.Ā This year, one of the fundraising locations will be at Opexaās corporate headquarters in The Woodlands. āOpexa is proud to be a partner of the National MS Societyās Houston area Walk MS events,ā said the President and Chief Executive Officer of Opexa,Ā Neil K. Warma. āWe are committed to helping the Society support critical programs and services to improve the quality of life for people affected by MS. We are dedicated to developing a personalized therapy for Secondary Progressive MS, and these events offer the unique opportunity for those of us in the Company to meet people living with MS and their families, which provides us with tremendous motivation.ā [adrotate group=”4″] The walk will serve as a meeting point for the MS Movement, a community coming together to raise funds and celebrate hope for the future for the more than 2.3 million people living with MS worldwide. Last year, the event was held in theĀ South Central Chapter’s territory, in which The Lone Star Chapter is also included, and brought together more than 25,000 people who helped raiseĀ $3.2 million for theĀ National Multiple Sclerosis Society. Since 1988,Ā Walk MS has been organized nationally, and has already raised more thanĀ $770 million to support programs, research, and new therapies. Opexa’s lead MS product isĀ Ā Tcelna,Ā aĀ breakthrough T-cell immunotherapyĀ for the treatment of MS. The company recently announced the end of patientĀ enrollment for their Phase IIb clinical trial to test a drug as a viable treatment forĀ Secondary Progressive MS. Print This Page About the Author Patricia Silva, PhD PatrĆcia holds a PhD in medical microbiology and infectious diseases from the Leiden University Medical Center, Netherlands, and completed a postdoctoral research fellowship at the Instituto de Medicina Molecular, Lisbon, Portugal. Her work in academia was mainly focused on molecular biology and the genetic traits of infectious agents such as viruses and parasites. PatrĆcia earned several travel awards to present her work at international scientific meetings. She is a published author of several peer-reviewed science articles. Tags National Multiple Sclerosis Society, Opexa Therapeutics, Walk MS
March 28, 2024 Columns by Benjamin Hofmeister Multiple sclerosis awareness is for people with MS, too
March 28, 2024 News by Lindsey Shapiro, PhD Restoring ‘lost’ pathway of neuroprotection benefits MS mice